What are the roles, specific uses, doses, and toxicity profiles of Colistin (polymyxin E) and Tigecycline, Zavicefta (ceftazidime + avibactam), and Meropenem (meropenem) + Vaborbactam in treating neutropenic sepsis in a patient undergoing TPF (taxane, platinum, 5-fluorouracil) chemotherapy?

Antibiotic Management of Neutropenic Sepsis in TPF Chemotherapy

Ceftazidime-Avibactam (Zavicefta)

For neutropenic sepsis with suspected or confirmed carbapenem-resistant Enterobacterales (CRE), ceftazidime-avibactam 2.5 g IV every 8 hours over 2 hours is the preferred first-line agent, with superior outcomes compared to polymyxin-based regimens. 1

Specific Indications

• Bloodstream infections from CRE: 2.5 g IV every 8 hours for 7-14 days 1
• Complicated urinary tract infections from CRE: 2.5 g IV every 8 hours for 5-7 days 1
• Complicated intra-abdominal infections from CRE: 2.5 g IV every 8 hours plus metronidazole 500 mg IV every 6 hours for 5-7 days 1
• Carbapenem-resistant Pseudomonas aeruginosa: Consider as alternative when ceftolozane-tazobactam unavailable 1

Dosing Adjustments

• CrCl 31-50 mL/min: 1.25 g IV every 8 hours 2
• CrCl 16-30 mL/min: 0.94 g IV every 12 hours 2
• CrCl 6-15 mL/min: 0.94 g IV every 24 hours 2

Toxicity Profile

• Nephrotoxicity: Significantly lower than polymyxin-based regimens (4% vs 24%) 3
• Common adverse effects: Diarrhea (8%), nausea (7%), vomiting (5%), headache (3%) 2
• Clostridioides difficile-associated diarrhea: Monitor all patients receiving treatment 2
• CNS reactions: Seizures, encephalopathy possible, especially with renal impairment—adjust dosing appropriately 2

Critical Considerations

• Monotherapy is recommended—do not add combination therapy for CRE susceptible to ceftazidime-avibactam 1
• Reserve for extensively resistant bacteria due to antibiotic stewardship—avoid for 3rd-generation cephalosporin-resistant Enterobacterales if other options available 1
• For metallo-beta-lactamase producers resistant to ceftazidime-avibactam: Combine with aztreonam 2 g IV every 6-8 hours 1, 4

---

Meropenem-Vaborbactam (Vabomere)

Meropenem-vaborbactam 4 g (meropenem 2 g + vaborbactam 2 g) IV every 8 hours over 3 hours is equally effective as ceftazidime-avibactam for CRE bloodstream infections, with clinical cure rates of 65.6% versus 33.3% for best available therapy. 1, 5, 3

Specific Indications

• CRE bloodstream infections: 4 g IV every 8 hours for 7-14 days 1, 5
• Complicated urinary tract infections from CRE: 4 g IV every 8 hours for 5-7 days 1, 5
• Complicated intra-abdominal infections: Not FDA-approved but guideline-supported 1

Dosing Adjustments

• CrCl 30-49 mL/min: 2 g (meropenem 1 g + vaborbactam 1 g) IV every 8 hours 5
• CrCl 15-29 mL/min: 2 g IV every 12 hours 5
• CrCl <15 mL/min: 1 g (meropenem 0.5 g + vaborbactam 0.5 g) IV every 12 hours 5
• Hemodialysis: Administer after dialysis session 5

Toxicity Profile

• Treatment-related adverse events: 24% (significantly lower than polymyxin-based therapy at 44%) 3
• Nephrotoxicity: 4% versus 24% with best available therapy 3
• Day-28 mortality: 15.6% versus 33.3% with polymyxin-based regimens 3
• Hypersensitivity reactions: Contraindicated in patients with beta-lactam anaphylaxis 5

Critical Considerations

• Monotherapy is recommended—combination therapy not needed for susceptible CRE 1
• Infuse over 3 hours to optimize pharmacodynamic targets 5
• Superior safety profile compared to colistin-based combinations, particularly regarding nephrotoxicity 3

---

Colistin (Polymyxin E)

Colistin should be reserved as a last-resort agent for CRE infections when newer beta-lactam/beta-lactamase inhibitors are unavailable or ineffective, always used in combination therapy due to high resistance emergence and nephrotoxicity. 1

Specific Indications

• CRE bloodstream infections (when ceftazidime-avibactam/meropenem-vaborbactam unavailable): Colistin 5 mg CBA/kg IV loading dose, then 2.5 mg CBA × (1.5 × CrCl + 30) IV every 12 hours PLUS tigecycline 100 mg IV loading, then 50 mg IV every 12 hours OR meropenem 1 g IV every 8 hours by extended infusion 1
• Carbapenem-resistant Pseudomonas aeruginosa: Combination therapy with beta-lactam when new agents unavailable 1

Dosing

• Loading dose: 5 mg colistin base activity (CBA)/kg IV 1
• Maintenance dose: 2.5 mg CBA × (1.5 × CrCl + 30) IV every 12 hours 1
• Conversion: 1 million international units (MIU) colistin methanesulfonate ≈ 33 mg CBA 1

Toxicity Profile

• Nephrotoxicity: 24% incidence, significantly higher than newer agents 3
• Neurotoxicity: Paresthesias, dizziness, confusion, neuromuscular blockade 1
• Mortality: Higher when used as monotherapy or in combination versus newer beta-lactam/beta-lactamase inhibitors 3

Critical Considerations

• Never use as monotherapy—always combine with tigecycline, meropenem, or other active agent 1
• Combination therapy suggested for clinically unstable patients with severe CRE infections 1
• Monitor renal function daily—adjust dose based on creatinine clearance 1
• Avoid if newer agents available—colistin-based regimens have 4-6 times higher nephrotoxicity than meropenem-vaborbactam 3

---

Tigecycline

Tigecycline should NOT be used for bloodstream infections or hospital-acquired/ventilator-associated pneumonia in neutropenic sepsis due to increased mortality; reserve for complicated intra-abdominal infections from CRE when newer agents unavailable. 1

Specific Indications

• Complicated intra-abdominal infections from CRE (when newer agents unavailable): 100 mg IV loading dose, then 50 mg IV every 12 hours for 5-7 days 1
• VRE complicated intra-abdominal infections: 50 mg IV every 12 hours after 100 mg loading dose 1

Dosing

• Loading dose: 100 mg IV 1
• Maintenance dose: 50 mg IV every 12 hours 1
• High-dose for pneumonia (if absolutely necessary): Consider higher doses, though still not recommended 1

Toxicity Profile

• Nausea/vomiting: Most common adverse effects 1
• Increased mortality: Particularly in bloodstream infections and pneumonia 1
• Hepatotoxicity: Monitor liver function tests 1

Critical Contraindications

• Strongly contraindicated for bloodstream infections 1
• Strongly contraindicated for hospital-acquired/ventilator-associated pneumonia 1
• Do not use for 3rd-generation cephalosporin-resistant Enterobacterales 1

Critical Considerations

• Only use in combination with colistin or meropenem for CRE complicated intra-abdominal infections when newer agents unavailable 1
• Suboptimal serum levels—poor choice for bacteremia 1
• Reserve as absolute last resort in neutropenic sepsis 1

---

Clinical Algorithm for Neutropenic Sepsis in TPF Chemotherapy

Step 1: Immediate Empirical Therapy (Within 1 Hour)

• Standard neutropenic sepsis: Meropenem 1-2 g IV every 8 hours OR piperacillin-tazobactam 4.5 g IV every 6 hours 6, 7
• Add vancomycin if severe mucositis, catheter-related infection suspected, or hemodynamic instability 6, 7

Step 2: Escalation for Persistent Fever or Suspected MDR Organisms

• If fever persists >72 hours OR known CRE colonization: Switch to ceftazidime-avibactam 2.5 g IV every 8 hours OR meropenem-vaborbactam 4 g IV every 8 hours 1
• If metallo-beta-lactamase suspected: Ceftazidime-avibactam 2.5 g IV every 8 hours PLUS aztreonam 2 g IV every 6-8 hours 1, 4

Step 3: Last-Resort Therapy (When All Else Fails)

• Colistin-based combination: Colistin 5 mg CBA/kg IV loading, then maintenance dosing PLUS tigecycline 100 mg IV loading, then 50 mg IV every 12 hours (for intra-abdominal source only) OR meropenem 1 g IV every 8 hours extended infusion 1

Step 4: Duration and De-escalation

• Total duration: 7-14 days depending on source and clinical response 1, 6, 7
• De-escalate when: Afebrile >72 hours, cultures identify specific pathogen, neutrophil recovery beginning 6, 7